China’s State FDA Says Merck Recalled Meningitis Vaccine (China)
This article was originally published in PharmAsia News
China's State FDA says U.S. drug maker Merck has recalled its Pedvaxhib (haemophilus b) conjugate vaccine for preventing meningitis and other diseases because of a sterilization problem in one of its U.S. factories. Merck said it recalled Pedvaxhib and similar Comvax vaccines after it discovered the sterilization problem in its Pennsylvania factory. No cases of children receiving Hib for preventing meningitis, pneumonia and other infections were reported, although infections usually take at least a week to develop. Hib is combined with a hepatitis B vaccine to prevent the other diseases. (Click here for more
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.